Phase II study of radiation with concomitant intra-arterial cisplatin infusion chemotherapy for maxillary sinus cancer - Phase II study of RADPLAT for maxillary sinus cancer

Tanaka Norimitsu0 个研究点目标入组 44 人开始时间: 2019年3月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Maxillary sinus cancer pathologically proved as squamous cell carcinoma
•2.Maxillary sinus cancer staged as T3 and T4 on UICC, 2009.
•3.No metastatic lymph node
•4.Primary treatment case
•5.Measurable disease
•6.Cather accessible case into the feeding arteries, including internal maxillary artery, facial artery and transverse facial artery.
•7.Pursuing of non-surgical and organ-preserving treatment, but salvage surgery for residual cancer can be done.
•8.Age of the patient: >=20 y.o. and <=75 y.o.
•9.Prognosis better than 8 months
•10. ECOG Performance status (PS) 0 or 1

•1)Bone suppression state
•2)Severe infection in the head and neck region
•3)Severe systemic complication, such as intestinal paralysis, ileus, interstitial pneumonitis, pulmonary fibrosis, uncontrolled DM, heart failure, renal failure, and liver failure.
•4)Synchronized active cancer
•5)History of irradiation for head and neck region
•6)History of allergy for cisplatin or contrast medium
•7)Severe mental disorder
•8)Pregnant, unwell to practice contraception during the study or lactating female
•9)Preoperative therapy for planed surgery
•10)Inaccessible catheterization due to arteriosclerosis
•11)Other causes judged unpreferable by attending physician for this protocol treatment

发起方

Tanaka Norimitsu